SecBot SecBot

SMMT

Summit Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001599298 Biotech & Drug Discovery
$11.82 −2.33 (−16.47%)
Nov 16 4:00 PM ET · prev $14.15
Market cap
$12.1B
Large cap
Consensus
Buy
71% Buy or better · 24 analysts
Median target
🔒 Subscribers only
1 year
−30.3%
from $16.95 · Nov 17
30 days
−24.1%
from $15.57
52-week range
$11.82–26.38
at the low
Avg volume 20D
5.75M
Nov 16 spike 24.43M
Short interest
42.26M
≈5.3% of shares · +3.3%
Days to cover
9.4
at average volume
Insider net
+$103.6M
3 buyers · 0 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
23
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 1 bearish · 5 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 8/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $103.6M at an average $13.17. No open-market sales. Price is 10% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 34 added (1 new), 13 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $29.0M.

  • AnalystsBULLISH

    17 of 24 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +3.3% to 42.26M shares. 9.4 days to cover, ≈5.3% of shares.

  • TrendDOWNTREND

    27% below its 50-day average. New closing low $11.82 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 1.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$29.0M
in new stakes
FundMoveSharesValue
STATE STREET CORPADD9,536,796$139.0M
UBS Group AGADD5,233,798$76.3M
GOLDMAN SACHS GROUP INCDOUBLED4,513,399$65.8M
PRICE T ROWE ASSOCIATES INC /MD/TRIM3,893,820$56.7M
Point72 Asset Management, L.P.DOUBLED3,697,803$53.9M
MILLENNIUM MANAGEMENT LLCDOUBLED2,349,081$34.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW1,989,591$29.0M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED1,904,254$27.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

24 analysts
Buy 71% rate it Buy or better
Strong Buy6Buy11Hold7Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 1, 2026Barclays
MAINTAIN
MAINTAINEqual-Weight
Sep 29, 2026Citigroup
MAINTAIN
MAINTAINBuy
Sep 23, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral

Insider ledger

Form 4
$103.6M
bought · 3 insiders
$0
sold · 0 insiders
−10.2%
vs their $13.17 cost
DateInsiderTypeValue
Oct 8, 2026
Anand Bhaskar
Chief Accounting Officer
Oct 8, 2026
AWARD100,000 sh
Jun 12, 2026
DUGGAN ROBERT W
Co-Chief Executive Officer
Jun 12, 2026
BUY$50.0M
Jun 12, 2026
Zanganeh Mahkam
Co-Chief Executive Officer
Jun 12, 2026
BUY$50.0M
Jun 4, 2026
Soni Manmeet Singh
COO and CFO
Jun 4, 2026
BUY$361.5K
Jun 4, 2026
Zanganeh Mahkam
Co-Chief Executive Officer
Jun 4, 2026
BUY$1.5M
Jun 4, 2026
DUGGAN ROBERT W
Co-Chief Executive Officer
Jun 4, 2026
BUY$1.5M
Jun 4, 2026
Soni Manmeet Singh
COO and CFO
Jun 4, 2026
BUY$360.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
42,263,053
shares short
+3.3%
vs prior settlement
9.4
days to cover
≈5.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 14, 2026 FDA PDUFA
PDUFA: SMMT, ivonescimab in EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-TKI therapy, 2026-11-14
FDA target action date 2026-11-14 for SMMT (Summit Therapeutics Inc.). Drug: ivonescimab. Indication
Nov 4, 2026 SEC
Summit Therapeutics filed an 8-K to register a prospectus supplement for the resale of up to 108,955,369 common shares…
8-K · Impact 3/10
Nov 4, 2026 SEC
Summit Therapeutics reported Q3 2026 financial results with no revenue and a GAAP net loss of $208.4M ($0.26 per…
8-K · Impact 6/10
Oct 8, 2026 Insider
Anand Bhaskar was granted 100,000 shares
Chief Accounting Officer
Jun 30, 2026 Inst.
STATE STREET CORP · ADD
9,536,796 shares ($139.0M)
Jun 30, 2026 Inst.
UBS Group AG · ADD
5,233,798 shares ($76.3M)
Jun 12, 2026 Insider
DUGGAN ROBERT W bought 3,810,000 shares
Co-Chief Executive Officer @ $13.12 ($50.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

23 filings · 11 bullish · 2 bearish · 1 mixed · 9 neutral
All SMMT filing & press-release reports (23)